tetano
Editor, Senior Moderator
J Clin Virol Plus
. 2023 Feb;3(1):100130.
doi: 10.1016/j.jcvp.2022.100130. Epub 2022 Dec 18.
Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination
Latha Dulipsingh[SUP] 1 2 [/SUP], Maxine Lang[SUP] 3 [/SUP], Margaret R Diffenderfer[SUP] 3 [/SUP], Lisa Cook[SUP] 1 [/SUP], Jennifer Puff[SUP] 1 [/SUP], Lynn Diaz[SUP] 1 [/SUP], Lihong He[SUP] 3 [/SUP], Ernst J Schaefer[SUP] 3 4 [/SUP]
Affiliations
Abstract
Background: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has caused over 6 million deaths world-wide. In the pre-vaccination era, we noted a 5·3% SARS-CoV-2 IgG antibody positivity rate in 81,624 subjects.
Methods: Utilizing assays for serum SARS-CoV-2 spike (S) protein antibody (Roche) and neutralizing antibody (Diazyme), both >90% IgG, we measured antibodies in 13,189 subjects in the post-vaccination era, and in 69 subjects before and 60 days after booster vaccination.
Results: In 2021, in 10,267 subjects, 25·0% had negative S protein levels (<0.80 U/L), 24·4% had low positive levels (0.80-250 U/L), and 50·7% had high positive levels (>250 U/L). Median neutralizing antibody levels were 1·16 and 2·06 AU/mL in the low and high positive groups, respectively. In 2022, we evaluated 2,016 subjects where samples were diluted 1:100 if S protein antibody levels were >250 U/L. Median S protein and neutralizing antibody levels were 2,065 U/L (86.3% positivity) and 2·68 AU/mL (68.0% positivity), respectively. Antibody levels were also measured in 69 subjects before and 60 days after receiving SARS-CoV-2 booster vaccinations. Treatment resulted in a 15-fold increase in S protein antibody levels from 1,010 to 17,236 U/L, and a 6-fold increase in neutralizing antibody from 1·51 to 12·51 AU/mL in neutralizing antibody levels, respectively (both P<0.00001), with a wide variability in response.
Conclusions: Our data indicate that by early 2022 86% of subjects had positive SARS-CoV-2 S protein antibody levels, and that these levels and neutralizing antibody levels were increased 15-fold and 6-fold, respectively, 60 days after SARS-Cov-2 booster vaccination.
Keywords: Neutralizing antibodies; Pre booster and post booster serology; S protein antibodies; SARS-CoV 2.
. 2023 Feb;3(1):100130.
doi: 10.1016/j.jcvp.2022.100130. Epub 2022 Dec 18.
Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination
Latha Dulipsingh[SUP] 1 2 [/SUP], Maxine Lang[SUP] 3 [/SUP], Margaret R Diffenderfer[SUP] 3 [/SUP], Lisa Cook[SUP] 1 [/SUP], Jennifer Puff[SUP] 1 [/SUP], Lynn Diaz[SUP] 1 [/SUP], Lihong He[SUP] 3 [/SUP], Ernst J Schaefer[SUP] 3 4 [/SUP]
Affiliations
- PMID: 36568023
- PMCID: PMC9759815
- DOI: 10.1016/j.jcvp.2022.100130
Abstract
Background: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has caused over 6 million deaths world-wide. In the pre-vaccination era, we noted a 5·3% SARS-CoV-2 IgG antibody positivity rate in 81,624 subjects.
Methods: Utilizing assays for serum SARS-CoV-2 spike (S) protein antibody (Roche) and neutralizing antibody (Diazyme), both >90% IgG, we measured antibodies in 13,189 subjects in the post-vaccination era, and in 69 subjects before and 60 days after booster vaccination.
Results: In 2021, in 10,267 subjects, 25·0% had negative S protein levels (<0.80 U/L), 24·4% had low positive levels (0.80-250 U/L), and 50·7% had high positive levels (>250 U/L). Median neutralizing antibody levels were 1·16 and 2·06 AU/mL in the low and high positive groups, respectively. In 2022, we evaluated 2,016 subjects where samples were diluted 1:100 if S protein antibody levels were >250 U/L. Median S protein and neutralizing antibody levels were 2,065 U/L (86.3% positivity) and 2·68 AU/mL (68.0% positivity), respectively. Antibody levels were also measured in 69 subjects before and 60 days after receiving SARS-CoV-2 booster vaccinations. Treatment resulted in a 15-fold increase in S protein antibody levels from 1,010 to 17,236 U/L, and a 6-fold increase in neutralizing antibody from 1·51 to 12·51 AU/mL in neutralizing antibody levels, respectively (both P<0.00001), with a wide variability in response.
Conclusions: Our data indicate that by early 2022 86% of subjects had positive SARS-CoV-2 S protein antibody levels, and that these levels and neutralizing antibody levels were increased 15-fold and 6-fold, respectively, 60 days after SARS-Cov-2 booster vaccination.
Keywords: Neutralizing antibodies; Pre booster and post booster serology; S protein antibodies; SARS-CoV 2.